Wunderlich Securities Reiterates Buy and PT of $18 on Abiomed (ABMD)

Wunderlich Securities reiterated its price target on Abiomed

. At the same time, Wunderlich left its rating unchanged at Buy. In a research report published today, Wunderlich stressed it remains very optimistic about Abiomed's long term outlook, citing high quality products and takeover possibilities. In the report, Wunderlich states, "We reiterate our Buy recommendation and $18 price target on Abiomed. Our target assumes a 5x EV/sales multiple on estimated 2012 revenues. We continue to view Impella as one of the most exciting technologies within the medical device sector, and we believe Abiomed is an attractive takeover target for one of the larger medical device companies." On Monday, Abiomed lost 2.01% of its value to close the day at $17.31.